Immusoft

Immusoft is a private, preclinical-stage biotech based in Seattle, pioneering a novel cell therapy platform that reprograms a patient's own B cells into long-lived protein factories. Its lead program, ISP-001, targets Mucopolysaccharidosis type I (MPS I), with the goal of providing a one-time, potentially curative treatment by enabling the body to continuously produce the missing enzyme. The company's technology, if successful, could disrupt the treatment paradigm for a wide range of protein-deficient diseases, offering advantages in durability, manufacturability, and patient convenience over traditional enzyme replacement therapies or other gene therapy approaches.

Immune System Programming (ISP™): An ex vivo cell therapy platform that genetically engineers a patient's own B cells to differentiate into long-lived plasma cells that continuously produce and secrete therapeutic proteins.

In MPS I, competition includes standard enzyme replacement therapy (e.g., Sanofi's Aldurazyme) and investigational gene therapies. Broader platform competitors include in vivo gene therapy companies (using AAV or lentiviral vectors) and other ex vivo engineered cell therapy approaches (e.g., CAR-T, stem cell gene therapy). Immusoft's unique focus on B/plasma cells is a key differentiator.